• Blog
  • Pricing
  • Contact
  • FAQ
Sign InSign Up
AI Agent for Financial MarketsAsk anything. Our AI Agent brings real-time data and full market coverage.Open chat
MarketsStocksCryptoForexCommoditiesCalendarInsiders
BIIB

BIIB

Biogen Inc.

NASDAQHealthcareDrug Manufacturers - GeneralUS

USD195.96

+7.13 (+3.78%)

Rating:A-

Company Profile

CEO

Christopher A. Viehbacher

IPO Date

1991-09-17

Sector

Healthcare

Industry

Drug Manufacturers - General

Exchange

NASDAQ

Country

US

Market Metrics

Open

$187.69

Prev. Close

$188.83

Day Low

$187.48

Day High

$196.36

52W Low

$121.05

52W High

$205.97

Market Cap

$28.93B

Volume

0.89M

OverviewFinancialsRatingsInsidersSentimentsChart Patterns
News SentimentBearish

Articles

10

Avg Positive

10.0%

Avg Negative

56.7%

Avg Neutral

33.2%

News Feed

Italy's antitrust regulator opens probe into US Biogen over alleged dominant position

reuters.com·5/27/2026·↓ negative

Leqembi Isn't Enough To Save Biogen Momentum (Rating Downgrade)

seekingalpha.com·5/26/2026·↓ negative

Denali Stock Dips as Biogen-Partnered Parkinson's Disease Study Fails

zacks.com·5/22/2026·↓ negative

Biogen Inc. (BIIB) Securities Fraud Investigation - Levi & Korsinsky

prnewswire.com·5/22/2026·↓ negative

Biogen Stock Slides After Trial Miss, But Analysts Stay Bullish

marketbeat.com·5/22/2026·↓ negative

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc. - BIIB

prnewswire.com·5/21/2026·↓ negative

Biogen, Denali scrap Parkinson's drug after failure in mid-to-late stage study

reuters.com·5/21/2026·↓ negative

Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson's Disease

globenewswire.com·5/21/2026·↑ positive

Levi & Korsinsky Announces Investigation of Securities Claims Against Biogen Inc. (BIIB)

globenewswire.com·5/20/2026·↓ negative

BIIB Investor Alert: Levi & Korsinsky Investigates Biogen Inc. (BIIB) for Potential Securities Fraud

businesswire.com·5/19/2026·↓ negative